
==== Front
Ophthalmol Ther
Ophthalmol Ther
Ophthalmology and Therapy
2193-8245
2193-6528
Springer Healthcare Cheshire

39150602
1016
10.1007/s40123-024-01016-8
Original Research
Clinical Outcomes of Excisional Goniotomy with the Kahook Dual Blade: 6-Year Results
Vasu Pranav 1
Abubaker Yazan 2
Boopathiraj Nithya 2
Wagner Isabella V. 2
Lentz P. Connor 23
Dorairaj Emily 4
Shokair Aya 5
Qozat Ibrahim 2
Miller Darby D. 2
Dorairaj Syril dorairaj.syril@mayo.edu

2
1 https://ror.org/05wf30g94 grid.254748.8 0000 0004 1936 8876 Department of Medicine, Creighton University School of Medicine, Phoenix, AZ USA
2 https://ror.org/02qp3tb03 grid.66875.3a 0000 0004 0459 167X Department of Ophthalmology, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL USA
3 https://ror.org/02qp3tb03 grid.66875.3a 0000 0004 0459 167X Department of Ophthalmology, Mayo Clinic Alix School of Medicine, Jacksonville, FL USA
4 Department of Medicine, Charles E. Schmidt College of Medicine, Boca Raton, FL USA
5 https://ror.org/03nawhv43 grid.266097.c 0000 0001 2222 1582 Department of Medicine, University of California Riverside School of Medicine, Riverside, CA USA
16 8 2024
16 8 2024
10 2024
13 10 27312744
2 7 2024
29 7 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by-nc/4.0/ Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
Introduction

This study aims to evaluate the long-term clinical outcomes of excisional goniotomy with the Kahook Dual Blade (KDB) in the management of various types of glaucoma.

Methods

This was a retrospective, noncomparative chart review of 90 eyes of 53 patients with glaucoma that underwent standalone KDB goniotomy (KDB-alone group) or KDB goniotomy with concomitant phacoemulsification (KDB-phaco group) between October 2015 and October 2017. Surgical success was defined as an intraocular pressure (IOP) reduction by ≥ 20% at the last follow-up with no surgical reinterventions required and a final IOP ≥ 4 mmHg and ≤ 21 mmHg. We also report on changes from baseline in IOP, number of glaucoma medications, best-corrected visual acuity (BCVA), and visual field parameters, for up to 72 months.

Results

At 72 months, mean (standard deviation [SD]) IOP was reduced from 17.5 (5.7) to 13.6 (3.0) mmHg (P < 0.0001) in the KDB-phaco group and from 23.3 (5.9) to 15.1 (6.2) mmHg (P = 0.0593) in the KDB-alone group. The mean (SD) number of glaucoma medications was reduced from 1.3 (1.0) to 0.8 (0.9) (P < 0.0001) in the KDB-phaco group and from 1.2 (1.0) to 0.7 (0.8) (P = 0.3409) in the KDB-alone group. During the 72-month follow-up, surgical success was achieved in 24 of the 52 available eyes (46.2%). Four eyes underwent a glaucoma surgical reintervention by 72 months.

Conclusions

Excisional goniotomy with the KDB effectively lowered the IOP (by an average of 28.0% from baseline) and maintained or further reduced glaucoma medication burdens (by an average of 30.8% from baseline) under an excellent safety profile, independent of phacoemulsification status. The procedure exhibited favorable success for up to 6 years, providing valuable insights into its long-term efficacy as a glaucoma treatment.

Supplementary Information

The online version contains supplementary material available at 10.1007/s40123-024-01016-8.

Keywords

Glaucoma
Goniotomy
Intraocular pressure
IOP-lowering medications
Phacoemulsification
Minimally invasive glaucoma surgery
issue-copyright-statement© Springer Healthcare Ltd., part of Springer Nature 2024
==== Body
pmcKey Summary Points

Within the literature, there is an abundance of reports documenting short-term outcomes of Kahook Dual Blade (KDB) excisional goniotomy; however, the longest study (5-year follow-up) within the current literature is limited to the inclusion of successful outcomes.	
We aimed to provide a study with the longest follow-up duration currently documented with real-world data.	
This study aims to assess the therapeutic capability of the KDB for the long-term management of various glaucoma etiologies, as measured by a mean 28.0% reduction from baseline in intraocular pressure (IOP) and a mean 30.8% reduction from baseline in glaucoma medication burden.	
The outcomes of this study demonstrate an exceptional safety profile and a 46% success rate over 6 years of follow-up.	
This work underscores the favorable selection of KDB among a plethora of minimally invasive glaucoma surgeries (MIGSs) and confirms its utility as a safe and effective therapy for glaucoma. This research may help direct further investigation on the safety and efficacy of KDB excisional goniotomy as a standalone procedure, as opposed to with concomitant phacoemulsification.	

Introduction

Within the past two decades, the glaucoma surgical armamentarium has seen a significant expansion with the introduction of minimally invasive glaucoma surgeries (MIGSs). MIGSs are advantageous in that they can be performed in earlier stages of the glaucoma disease course and delay the need for more invasive incisional procedures, with up to 10 years of stable intraocular pressure (IOP) maintenance currently reported within the literature [1, 2]. Additionally, these procedures possess lower procedural risks, shorter operation times, and faster patient recovery times when compared to traditional surgical interventions [3]. Performing MIGS can reduce the vision-threatening complications associated with traditional incisional procedures, such as endophthalmitis, hypotony, and choroidal effusion [4]. Typically, MIGS procedures fall into one of three categories: (1) MIGSs that increase uveoscleral outflow; (2) MIGSs that reroute the flow of aqueous humor to the subconjunctival space; and (3) MIGSs that divert the flow of aqueous humor to the Schlemm’s canal [5].

The Kahook Dual Blade (KDB; New World Medical Inc. Rancho Cucamonga, CA, USA) is an “angle-based” MIGS device that aims to increase conventional outflow by diverting aqueous egress to the Schlemm’s canal. Similar to gonioscopy-assisted transluminal trabeculotomy, this procedure is bleb-independent and minimally invasive [6]. The KDB is intended to perform excisional goniotomy and possesses two parallel blades that allow for a complete and uniform excision of a strip of trabecular meshwork, limiting the inflammation and scleral damage seen in traditional goniotomy procedures [7]. The current literature reports primarily on the outcomes of KDB goniotomy—with and without phacoemulsification—in open-angle glaucoma (OAG) [8–14], but the procedure has also demonstrated success in angle-closure glaucoma (ACG) [15–18]. Studies within the literature support a favorable safety and efficacy profile for KDB goniotomy, reporting notable reductions in IOP by 20–30% from baseline and a decrease in glaucoma medication burden by 1–3 medications [8–14].

Currently, long-term outcomes of KDB goniotomy require further investigation. Within the PubMed-indexed literature, there is one study evaluating 5-year outcomes with the device [14], but its findings are limited by the inclusion of successful outcomes only. This study aims to document clinical safety and efficacy outcomes of KDB goniotomy with or without concomitant phacoemulsification over a 6-year period in a real-world setting.

Methods

A retrospective, single surgeon (S.D.), noncomparative study was conducted at the Mayo Clinic. The study protocol was reviewed and approved by the Mayo Clinic Institutional Review Board (IRB) on February 28, 2018 (IRB Number: 18-000006). This study was conducted in accordance with the tenets of the Declaration of Helsinki of 1964 and its later amendments. All patient data were deidentified, and informed consent was waived by the Mayo Clinic IRB. Patients aged ≥ 18 years diagnosed with glaucoma that received excisional goniotomy with the KDB between October 1, 2015 and October 31, 2017 were included within this study. All glaucoma subtypes were eligible for inclusion.

Excisional goniotomy with the KDB was carried out in accordance with the manufacturer’s guidelines. The procedure began with the sharp tip of the device being introduced through a clear corneal incision, targeting the nasal angle. The tip was used to puncture the trabecular meshwork while the heel of the device was positioned against Schlemm’s canal. The device was then moved for four clock hours in a clockwise or counterclockwise direction, creating two parallel incisions to remove a strip of trabecular meshwork, ensuring no damage to surrounding structures. After the excision, the KDB blade was extracted from the eye. In cases involving combined phacoemulsification, KDB goniotomy was executed after the successful implantation of the intraocular lens.

Participants were evaluated preoperatively, intraoperatively, and postoperatively on day 1, week 1, and months 1, 3, 6, 12, 24, 36, 48, 60, and 72. Pre- and postoperative data included IOP, number of glaucoma medications required, best-corrected visual acuity (BCVA), and visual field parameters—pattern standard deviation (PSD) and mean deviation (MD). Medications utilized for glaucoma management included alpha-agonists, beta-blockers, carbonic anhydrase inhibitors, prostaglandin analogs, pilocarpine, and various combination eyedrops of the aforementioned medications. An assessment of IOP, cup–disc ratio, and visual fields were utilized to determine the number of medications necessary. IOP was measured using Goldmann applanation tonometry, and BCVA was assessed using a Snellen eye chart at 20 feet. Baseline measurements were assessed one day prior to surgery for all patients. Slit-lamp and fundus examinations were used to visualize and evaluate the anterior and posterior segments of each eye. Standard automatic perimetry was performed using a Humphrey field analyzer (Carl Zeiss Meditec Inc., Dublin, CA, USA). Glaucoma severity was classified based upon the International Classification of Diseases, Tenth Revision [19].

Standard descriptive statistics were used to report demographics and baseline characteristics, with means and standard deviations (SD) used for continuous variables, and percentages used for categorical variables. Normality of continuous variables was confirmed, and subsequent paired two-tailed t tests were used wherein a p value of less than 0.05 was considered statistically significant. Kaplan–Meier survival curves were utilized to analyze the surgical success probability in the cumulative cohort. Surgical success was defined as an IOP reduction of ≥ 20% with no surgical reintervention required and a final IOP ≥ 4 mmHg and ≤ 21 mmHg. All statistical analyses were performed with GraphPad Prism (GraphPad Version 10.2.3; GraphPad Software, Boston, MA, USA).

Results

Demographic and Preoperative Glaucoma Status

Ninety eyes of 53 patients that underwent KDB excisional goniotomy with or without concomitant phacoemulsification with ≥ 12 months of follow-up were eligible for inclusion. Data from 52 eyes (58%) were available at 72 months.

Demographic information of patients and baseline characteristics are detailed in Table 1. The mean (SD) age of all patients was 71.2 (7.4) years and the majority of patients were White (72%) and female (66%). There were 72 eyes (80%) that underwent combined KDB and phacoemulsification (KDB-phaco group), while 18 eyes (20%) underwent KDB as a standalone procedure (KDB-alone group). All eyes that underwent standalone KDB were pseudophakic. Various glaucoma etiologies were represented, including POAG (63%), pseudoexfoliative glaucoma (4%), steroid-induced glaucoma (7%), and PACG (26%). Of the total sample, ten eyes (11%) had mild glaucoma, 55 eyes (61%) had moderate glaucoma, and 25 eyes (28%) had severe glaucoma. Thirty-six eyes (40%) were surgically naïve at baseline (Table 1).Table 1 Demographic and preoperative glaucoma status of study patients

	Total sample	KDB-phaco group	KDB-alone group	
No. of patients, n	53	41	12	
Age (years), mean (SD)	71.4 (7.4)	70.9 (7.3)	73.0 (7.7)	
Gender, n (%)	
 Male	18 (34)	13 (32)	7 (58)	
 Female	35 (66)	28 (68)	5 (42)	
Ethnicity, n (%)	
 White	38 (72)	28 (68)	10 (83)	
 Black	8 (15)	7 (17)	1 (8)	
 Asian	4 (7)	3 (7)	1 (8)	
 Hispanic	1 (2)	1 (2)	0 (0)	
 Not disclosed	2 (4)	2 (5)	0 (0)	
No. of eyes, n	90	72	18	
Diagnosis, n (%)	
 Primary open-angle glaucoma	57 (63)	42 (58)	15 (83)	
 Pseudoexfoliative glaucoma	4 (4)	2 (3)	2 (13)	
 Steroid-induced	6 (7)	5 (6)	0 (0)	
 Primary angle closure glaucoma	23 (26)	22 (31)	1 (6)	
Glaucoma severity, n (%)	
 Mild	10 (11)	10 (14)	0 (0)	
 Moderate	55 (61)	43 (60)	12 (67)	
 Severe	25 (28)	19 (26)	6 (33)	
Laterality, n (%)	
 Right eye	46 (51)	37 (51)	9 (50)	
 Left eye	44 (49)	35 (49)	9 (50)	
Previous glaucoma procedures, n (%)	
 No previous glaucoma procedures	36 (40)	30 (42)	6 (33)	
SD standard deviation, KDB Kahook Dual Blade

Mean IOP, Glaucoma Medication Use, and BCVA at Baseline and Each Postoperative Visit in All Eyes

Table 2 outlines the mean IOP, glaucoma medication burden, and BCVA in all eyes from baseline to 72 months. IOP progression of the total sample can be found in Fig. 1. IOP ranged from 13.3–15.7 mmHg (Fig. 1) across months 6–72, representing mean percent reductions ranging from 12.4–31.1% (P < 0.05 at every time point). The mean (SD) IOP decreased from 18.6 (6.2) mmHg at baseline to 13.9 (3.9) mmHg at 72 months (− 28.0%). Medication dependency progression of the total sample can be found in Fig. 2. Mean medication dependency ranged from 0.8 to 1.2 medications (Fig. 2) between months 6–72. The mean (SD) number of glaucoma medications required at baseline was 1.3 (1.0) and was reduced to 0.8 (0.9) at 72 months (− 30.8%). LogMAR BCVA was recorded at each follow-up visit; however, significant changes from baseline in BCVA were not observed at 72 months (Table 2).Table 2 Mean intraocular pressure, medication use, and best-corrected visual acuity at each study visit in all eyes combined

	Baseline	6 Months	12 Months	24 Months	36 Months	48 Months	60 Months	72 Months	
Number of eyes, n	90	69	78	61	63	60	54	52	
Intraocular pressure, mmHg	
 Mean (SD)	18.6 (6.2)	13.3 (3.4)	14.3 (4.1)	15.8 (4.8)	15.6 (4.2)	15.7 (4.2)	14.8 (5.4)	13.9 (3.9)	
 Change from baseline		− 5.8	− 4.7	− 2.3	− 3.7	− 3.2	− 3.2	− 5.2	
 Change from baseline (%)		− 31.1%	− 25.3%	− 12.4%	− 19.9%	− 17.2%	− 17.2%	− 28.0%	
 Significance (P)		 < 0.0001	 < 0.0001	0.0155	 < 0.0001	0.0012	0.0079	 < 0.0001	
Medications, n	
 Mean (SD)	1.3 (1.0)	0.9 (0.9)	0.8 (0.8)	1.0 (0.9)	1.1 (1.0)	1.2 (1.2)	1.2 (1.1)	0.8 (0.9)	
 Change from baseline		− 0.5	− 0.5	− 0.4	− 0.2	− 0.2	− 0.2	− 0.4	
 Change from baseline (%)		− 38.5%	− 38.5%	− 30.8%	− 15.4%	− 15.4%	− 15.4%	− 30.8%	
 Significance (P)		 < 0.0001	 < 0.0001	0.0018	0.0045	0.0573*	0.1533*	 < 0.0001	
Best-corrected visual acuity, logMAR	
 Mean (SD)	0.261 (0.224)	0.119 (0.177)	0.145 (0.272)	0.159 (0.379)	0.173 (0.396)	0.196 (0.387)	0.299 (0.552)	0.261 (0.472)	
 Change from baseline		− 0.166	− 0.118	− 0.137	− 0.106	− 0.078	0.000	− 0.028	
 Significance (P)		 < 0.0001	0.0003	0.0039	0.0270	0.1474*	0.9987*	0.6018*	
SD standard deviation

*P value not statistically significant (P > 0.05)

Fig. 1 Mean intraocular pressure (IOP) over time in the study cohort. Error bars represent standard deviation

Fig. 2 Mean glaucoma medication use over time in the study cohort. Error bars represent standard deviation

Mean IOP, Glaucoma Medication Use, and BCVA at Baseline and Each Postoperative Visit in KDB-Phaco Group

IOP, glaucoma medication, and BCVA outcomes for the KDB-phaco group are outlined in Table 3. Reductions in IOP ranged from 2.9–5.6 mmHg between months 6–72, representing mean percent reductions ranging from 16.6–32.0% (P < 0.05 at every follow-up). The mean (SD) baseline IOP of 17.5 (5.7) mmHg was reduced to 13.6 (3.0) mmHg at 72 months (− 27.4%). Across all time points, the largest reduction in medication from baseline use occurred at 12 months (− 53.8%; P < 0.0001) and the smallest reduction occurred at 60 months (− 15.4%; P = 0.2290) (Table 3). The mean (SD) number of glaucoma medications was significantly reduced from 1.3 (1.0) at baseline to 0.8 (0.9) at 72 months (P < 0.0001). Baseline logMAR BCVA for KDB-phaco group was 0.283,and subsequent visits yielded a BCVA of 0.107, 0.121, 0.115, 0.142, 0.167, 0.227, and 0.247 logMAR at months 6, 12, 24, 36, 48, 60, and 72, respectively (P < 0.05 at months 6–48; P = 0.0696 at month 60; and P = 0.1734 at month 72).Table 3 Mean intraocular pressure, medication use, and best-corrected visual acuity at each study visit in the KDB-phaco group

	Baseline	6 Months	12 Months	24 Months	36 Months	48 Months	60 Months	72 Months	
Number of eyes, n	72	56	61	53	50	51	43	41	
Intraocular pressure, mmHg	
 Mean (SD)	17.5 (5.7)	12.6 (2.6)	13.5 (3.3)	14.9 (3.5)	14.6 (2.5)	15.6 (3.7)	15.1 (5.6)	13.6 (3.0)	
 Change from baseline		− 5.6	− 4.4	− 3.5	− 3.9	− 2.9	− 3.1	− 4.8	
 Change from baseline (%)		− 32.0%	− 25.1%	− 20.0%	− 22.2%	− 16.6%	− 17.7%	− 27.4%	
 Significance (P)		 < 0.0001	 < 0.0001	 < 0.0001	 < 0.0001	0.0026	0.0293	 < 0.0001	
Medications, n	
 Mean (SD)	1.3 (1.0)	0.7 (0.8)	0.7 (0.8)	0.9 (0.9)	1.0 (1.0)	1.2 (1.2)	1.1 (1.1)	0.8 (0.9)	
 Change from baseline		− 0.6	− 0.7	− 0.4	− 0.3	− 0.2	− 0.2	− 0.5	
 Change from baseline (%)		− 46.2%	− 53.8%	− 30.1%	− 23.1%	− 15.4%	− 15.4%	− 38.5%	
 Significance (P)		 < 0.0001	 < 0.0001	0.0007	0.0004	0.1514*	0.2290*	 < 0.0001	
Best-corrected visual acuity, logMAR	
 Mean (SD)	0.283 (0.238)	0.107 (0.185)	0.121 (0.262)	0.115 (0.278)	0.142 (0.322)	0.167 (0.390)	0.227 (0.465)	0.247 (0.495)	
 Change from baseline		− 0.192	− 0.165	− 0.194	− 0.161	− 0.130	− 0.097	− 0.076	
 Significance (P)		 < 0.0001	 < 0.0001	 < 0.0001	0.0005	0.0258	0.0696*	0.1734*	
SD standard deviation, KDB Kahook Dual Blade

*P value not statistically significant (P > 0.05)

Mean IOP, Glaucoma Medication Use, and BCVA at Baseline and Each Postoperative Visit in KDB-alone Group

IOP, glaucoma medication, and BCVA outcomes for the KDB-alone group are reported in Table 4. The KDB-alone cohort included 18 eyes at baseline, with 11 remaining after 6 years. Across all time points, the average reduction in IOP was 24.4%. Statistical significance was achieved at 6, 12, and 60 months (P < 0.05). The mean (SD) IOP of 23.3 (5.9) mmHg was reduced to 15.1 (6.2) mmHg (− 28.8%) at 72 months. A scatterplot of IOP progression across all visits can be found in the Supplementary Material. The baseline mean (SD) number of glaucoma medications was reduced from 1.2 (1.0) to 0.7 (0.8) at 72 months (− 41.7%). Statistical significance for medication burden reduction was not achieved at any follow-up visit. Changes in BCVA for eyes within this group were not reported.Table 4 Mean intraocular pressure, medication use, and best-corrected visual acuity at each study visit in the KDB-alone group

	Baseline	6 Months	12 Months	24 Months	36 Months	48 Months	60 Months	72 Months	
Number of eyes, n	18	13	17	9	13	10	11	11	
Intraocular pressure, mmHg	
 Mean (SD)	23.3 (5.9)	16.5 (4.4)	17.2 (5.5)	21.4 (7.2)	19.5 (6.7)	15.8 (6.3)	13.4 (4.7)	15.1 (6.2)	
 Change from baseline		− 6.4	− 5.8	− 2.6	− 2.9	− 6.9	− 9.1	− 6.7	
 Change from baseline (%)		− 27.5%	− 24.9%	− 11.2%	− 12.4%	− 29.6%	− 39.0%	− 28.8%	
 Significance (P)		0.0205	0.0132	0.3295*	0.1628*	0.0616*	0.0066	0.0593*	
Medications, n	
 Mean (SD)	1.2 (1.0)	1.4 (1.1)	1.1 (1.0)	2.0 (0.7)	1.5 (1.1)	1.1 (1.3)	1.5 (1.2)	0.7 (0.8)	
 Change from baseline		0.0	− 0.2	0.1	0.15	− 0.4	− 0.3	− 0.3	
 Change from baseline (%)		 + 16.7%	− 8.3%	 + 66.7%	 + 25.0%	− 8.3%	 + 25.0%	− 41.7%	
 Significance (P)		 > 0.9999*	0.4220*	0.5843*	0.3370*	0.1679*	0.4850*	0.3409*	
SD standard deviation, KDB Kahook Dual Blade

*P value not statistically significant (P > 0.05)

Visual Field Outcomes

Changes in visual field mean deviation (VF-MD) and pattern standard deviation (VF-PSD) can be found in Table 5, Figs. 3, and 4. At baseline, VF-MD was − 3.56 dB, which over 72 months dropped to − 5.32 dB (P = 0.0222) (Fig. 3). VF-PSD did not yield significant differences from 3.83 dB at baseline to 4.93 at 72 months (P = 0.1464) (Fig. 4).Table 5 Baseline and post-operative visual field parameters at each annual visit, through 6 years

	Baseline	12 Months	24 Months	36 Months	48 Months	60 Months	72 Months	
VF-mean deviation (dB), mean (SD)	− 3.56 (5.19)	− 3.77 (6.51)	− 5.30 (6.48)	− 6.54 (7.39)	− 5.62 (7.26)	− 4.65 (6.61)	− 5.32 (7.70)	
Significance (P)		0.3711*	0.1998*	0.0019	0.0048	0.0297	0.0222	
VF-pattern SD (dB), mean (SD)	3.83 (3.23)	4.00 (3.70)	4.67 (3.72)	4.98 (4.12)	5.17 (3.96)	4.64 (3.47)	4.93 (4.11)	
Significance (P)		0.2212*	0.0461	0.0328	0.0038	0.1111*	0.1464*	
SD standard deviation, VF visual field

*P value not statistically significant (P > 0.05)

Fig. 3 Annual visual field mean deviation (VF-MD) over time. Error bars represent standard deviation

Fig. 4 Annual visual field pattern standard deviation (VF Pattern SD) over time. Error bars represent standard deviation

Surgical Success

At 72 months, 24 of the 52 remaining eyes (46.2%) met surgical success, as defined by the success criteria of > 20% IOP reduction from baseline with no surgical reintervention and an IOP between 4 and 21 mmHg. The success rate for the total sample from the baseline 90 patients using the last follow-up visit of the remaining 52 patients was 26.7%. Four eyes underwent a surgical reintervention and were deemed to have failed. Median duration of surgical success was 48 months. A Kaplan–Meier survival curve of surgical success probability can be found in Fig. 5.Fig. 5 The cumulative probability of success for Kahook Dual Blade (KDB) goniotomy over 6 years

Complications

A summary of postoperative complications can be found in Table 6. All complications were minor and self-limited, with no severe or sight-threatening complications observed. IOP spike (defined as an increase in IOP > 10 mmHg or a transient measurement of 30 mmHg within 1-month postoperatively) was observed in three eyes (3.3%) and resolved spontaneously. Four eyes (4.4%) required surgical re-intervention with canaloplasty (Table 6).Table 6 Complications observed in combined cohort over a 6-year follow-up period

Complication	N (%)	
Intraocular pressure spike > 10 mmHg or a transient measurement of 30 mmHg within 1-month postoperatively	3 (3.3)	
Surgical reintervention with canaloplasty	4 (4.4)	

Discussion

In this retrospective study, we report clinical and safety efficacy data from a cohort of patients who were followed longitudinally over 6 years after undergoing KDB excisional goniotomy, either as a standalone procedure or combined with cataract surgery. All procedures were performed at the same center by a single surgeon, ensuring consistency and validity of the surgical technique and results. To the best of our knowledge, this analysis represents the longest published follow-up of KDB goniotomy outcomes to date.

Compared to the existing literature on outcomes of KDB with and without phacoemulsification [8–18, 20–26], similar outcomes in terms of average IOP (− 28.0%) and medication reductions (− 30.8%) were observed. The current literature indicates that an average IOP reduction of 20–37% is expected and commonly seen with follow-up periods ranging from 12 months until 36 months [8–17]. Moreover, the preoperative IOP (18.6 mmHg) and postoperative IOP (13.9 mmHg) of the total sample was generally similar to the range reported in the existing publications on trabecular MIGSs [3, 8–10, 12–18, 22, 24, 27]. Statistically and clinically significant reductions in IOP and medication burden were observed in the cumulative cohort after 6 years, demonstrating the long-term efficacy of the KDB procedure. Additionally, minimal early post-operative and intraoperative complications were observed, highlighting the excellent safety profile of the KDB. Notably, there was a complete absence of post-operative endophthalmitis, hypotony, Descemet membrane detachment, and posterior capsule opacification, as would commonly be expected with other MIGSs [28].

The KDB-phaco group exhibited statistically significant reductions in IOP at all follow-up visits. Apart from the 4- and 5-year visits, this cohort also showed statistically significant reductions in medication burden. The variability in medication dependence is noteworthy and can likely be attributed to poor medication compliance and reduced communication with physicians, compounded by the COVID-19 pandemic. Patients underwent KDB excisional goniotomy between 2015 and 2017, causing several 4- and 5-year follow-up visits to occur between 2020 and 2021. Poor compliance with medication during this period may have resulted in unexpected disease progression as indicated by visual field changes, despite stable IOPs, necessitating an increase in prescribed medications.

The KDB-alone group yielded promising reductions from baseline in IOP, with percent decreases ranging from 11.2–39.0% across all follow-up visits. However, these reductions did not reach statistical significance at 2, 3, 4, or 6 years. Notably, at 12 and 24 months, a transient increase in IOP was observed, illustrated by the scatter plot shown in the Supplementary Material. This occurred primarily due to a single patient who experienced surgical failure requiring reintervention, with IOP measurements of 36 and 38 mmHg at 12 and 24 months, respectively. This cohort experienced a greater variability in IOP, likely due to its comparatively smaller sample size. As seen in the KDB-phaco group, several patients in the standalone group had follow-up visits scheduled during the COVID-19 pandemic, leading to inconsistencies in medication compliance, communication, and timely pressure monitoring. Additionally, it has been established that medication compliance is reduced in multi-drug regimens for glaucoma, exacerbating disease progression [29].

BCVA remained stable in the KDB-alone group and statistically significant improvements were noted in the KDB-phaco group, for up to 4 years of follow-up. Between 5 and 6 years, visual acuity appeared to approach the baseline value (0.283 logMAR) in KDB-phaco eyes. This trend can be attributed to the normal progression of ocular aging, with BCVA changes likely resulting from concurrent pathologies such as age-related macular degeneration (AMD) and diabetic retinopathy (DR) [30–32].

Visual fields were assessed using VF-MD and VF-PSD. At 6 years, VF-MD (SD) significantly decreased to − 5.32 (7.70) (P < 0.05) dB while PSD (SD) increased to 4.93 (4.11) dB (P = 0.1464), albeit not significantly. Significant changes in VF-MD and VF-PSD were observed at the 2-, 3-, and 4-year follow-up visits, but reintervention was avoided due to stable IOPs and cup-to-disc ratios in the affected eyes. It is worth noting that visual field measurements can be highly variable due to changes in testing settings and circumstances such as eye fatigue, movement within the testing room, and glaucoma severity [33, 34]. Furthermore, current literature states that the normal glaucomatous process and aging can produce significant changes is VF-MD up to − 0.80 dB per year in treated patients [35–40]. The results within this study fall well below this threshold throughout the follow-up period.

A study by Bravetti et al. discusses surgical success of KDB excisional goniotomy over a 12-month period with a similar success criteria of a ≥ 20% reduction in IOP [27]. Within this study, 37.5% of eyes exhibited surgical success over a substantially shorter follow-up duration [27], whereas our study exhibited a more favorable success rate of 46.2% at 6 years in the remaining eyes. With a median success of 4 years, KDB goniotomy provides promising long-term reliability for the management of glaucoma. This current study underscores the durability of treatment with KDB with exceptional 6-year success and can be interpreted as a safe and reliable option for management of various glaucoma subtypes.

This study offers valuable insights into the long-term safety and efficacy outcome of KDB excisional goniotomy. Advantages of this study include the inclusion of real-world outcomes encompassing both failures and successes, as well as the consistency and validity ensured by having all procedures performed by a single surgeon at the same center.

Limitations

Several limitations are present in this study. Firstly, the retrospective nature of this study did not allow for randomization. Secondly, several patients were lost to follow-up, affecting overall consistency of the results. Additionally, medication regimens were not standardized, potentially influencing the number of medications used. The various forms of glaucoma represented in this study may also serve as a potential limitation as it can cause variation in clinical outcomes. Provided the seniority of the patient population and convenience of concomitant cataract surgery with goniotomy, the KDB-alone group was relatively small. Finally, baseline measurements of IOP were not at a standardized time of day, resulting in potential for inconsistencies as the literature has established that IOP tends to peak in the early hours of the day—shortly after awakening from sleep [41]. Future studies are needed to evaluate the long-term efficacy and safety of standalone excisional goniotomy with the KDB.

Conclusions

Combined KDB excisional goniotomy and phacoemulsification demonstrated clinically significant reductions in IOP and clinically reduced medication burdens in patients with glaucoma. The procedure showed favorable success, even at 6 years post-operatively. KDB goniotomy appears to be a promising long-term therapy for correcting angle-closure and various forms of open-angle glaucoma.

Supplementary Information

Below is the link to the electronic supplementary material.Supplementary file1 (PDF 87 KB)

Acknowledgements

We thank the participants of the study. The authors acknowledge Ms. Joyce Baker for her generous contributions to the Department of Ophthalmology, Mayo Clinic, Jacksonville, FL, USA.

Author Contribution

Pranav Vasu—statistical analysis, drafting manuscript, data curation. Yazan Abubaker—data curation, drafting manuscript. Nithya Boopathiraj—concept and design, data curation. Isabella V. Wagner—concept and design, data curation, drafting manuscript. P. Connor Lentz—concept and design, data curation. Emily Dorairaj—data curation, drafting manuscript. Aya Shokair—drafting manuscript. Ibrahim Qozat—supervision, manuscript review. Darby D Miller—supervision, manuscript review. Syril Dorairaj—supervision, manuscript review.

Funding

No funding or sponsorship was received for the study or publication of this article. The Rapid Service Fee was funded by the authors.

Data Availability

The datasets generated during and/or analyzed during the current study may be available from the corresponding author on reasonable request.

Declarations

Conflict of Interest

Pranav Vasu, Yazan Abubaker, Nithya Boopathiraj, Isabella V. Wagner, P. Connor Lentz, Emily Dorairaj, Aya Shokair, Ibrahim Qozat, Darby D Miller, and Syril Dorairaj all have nothing to disclose.

Ethical Approval

The study protocol was reviewed and approved by the Mayo Clinic Institutional Review Board (IRB) on 28 February 2018 (IRB 18-000006). This study was conducted in accordance with the tenets of the Declaration of Helsinki of 1964 and its later amendments. Informed consent was waived by the Mayo Clinic IRB. All patient data has been deidentified, and no identifying information is present within this report.
==== Refs
References

1. Ahmed IIK MIGS and the FDA: what’s in a name? Ophthalmology 2015 122 1737 1739 10.1016/j.ophtha.2015.06.022 26299720
Ahmed IIK. MIGS and the FDA: what’s in a name? Ophthalmology. 2015;122:1737–9.26299720
2. Neuhann TH Neuhann RT Hornbeak DM Ten-year effectiveness and safety of trabecular micro-bypass stent implantation with cataract surgery in patients with glaucoma or ocular hypertension Ophthalmol Ther 2024 13 2243 2254 10.1007/s40123-024-00984-1 38907091
Neuhann TH, Neuhann RT, Hornbeak DM. Ten-year effectiveness and safety of trabecular micro-bypass stent implantation with cataract surgery in patients with glaucoma or ocular hypertension. Ophthalmol Ther. 2024;13:2243–54.38907091
3. Balas M Mathew DJ Minimally invasive glaucoma surgery: a review of the literature Vision 2023 7 54 10.3390/vision7030054 37606500
Balas M, Mathew DJ. Minimally invasive glaucoma surgery: a review of the literature. Vision. 2023;7:54.37606500
4. Zaifar A Pratomo TG Suryono AN Comparison between MIGS with trabeculectomy in the management of open-angle glaucoma with cataract: a systematic review Indian J Ophthalmol 2024 72 S345 S353 10.4103/IJO.IJO_1322_23 38648451
Zaifar A, Pratomo TG, Suryono AN. Comparison between MIGS with trabeculectomy in the management of open-angle glaucoma with cataract: a systematic review. Indian J Ophthalmol. 2024;72:S345–53.38648451
5. Wagner IV Stewart MW Dorairaj SK Updates on the diagnosis and management of glaucoma Mayo Clin Proc Innov Qual Outcomes 2022 6 618 635 10.1016/j.mayocpiqo.2022.09.007 36405987
Wagner IV, Stewart MW, Dorairaj SK. Updates on the diagnosis and management of glaucoma. Mayo Clin Proc Innov Qual Outcomes. 2022;6:618–35.36405987
6. Tekcan H İmamoğlu S Mangan MS Anterior segment changes and refractive outcomes after cataract surgery combined with gonioscopy-assisted transluminal trabeculotomy in open-angle glaucoma Turk J Ophthalmol 2023 53 369 376 10.4274/tjo.galenos.2023.36080 38047480
Tekcan H, İmamoğlu S, Mangan MS. Anterior segment changes and refractive outcomes after cataract surgery combined with gonioscopy-assisted transluminal trabeculotomy in open-angle glaucoma. Turk J Ophthalmol. 2023;53:369–76.38047480
7. Dorairaj S Radcliffe NM Grover DS Brubaker JW Williamson BK A review of excisional goniotomy performed with the Kahook Dual Blade for glaucoma management J Curr Glaucoma Pract 2022 16 59 64 10.5005/jp-journals-10078-1352 36060046
Dorairaj S, Radcliffe NM, Grover DS, Brubaker JW, Williamson BK. A review of excisional goniotomy performed with the Kahook Dual Blade for glaucoma management. J Curr Glaucoma Pract. 2022;16:59–64.36060046
8. Laroche D Nkrumah G Ugoh P Ng C Real-world outcomes of Kahook Dual Blade goniotomy in Black and Afro-Latinx adult patients with glaucoma: a 6-month retrospective study J Natl Med Assoc 2021 113 230 236 33158570
Laroche D, Nkrumah G, Ugoh P, Ng C. Real-world outcomes of Kahook Dual Blade goniotomy in Black and Afro-Latinx adult patients with glaucoma: a 6-month retrospective study. J Natl Med Assoc. 2021;113:230–6.33158570
9. Dorairaj SK 12-Month outcomes of goniotomy performed using the Kahook Dual Blade combined with cataract surgery in eyes with medically treated glaucoma Adv Ther 2018 35 1460 1469 10.1007/s12325-018-0755-4 30078175
Dorairaj SK, et al. 12-Month outcomes of goniotomy performed using the Kahook Dual Blade combined with cataract surgery in eyes with medically treated glaucoma. Adv Ther. 2018;35:1460–9.30078175
10. Barkander A Economou MA Jóhannesson G Kahook Dual-Blade goniotomy with and without phacoemulsification in medically uncontrolled glaucoma Clin Ophthalmol Auckl NZ 2023 17 1385 1394 10.2147/OPTH.S409375
Barkander A, Economou MA, Jóhannesson G. Kahook Dual-Blade goniotomy with and without phacoemulsification in medically uncontrolled glaucoma. Clin Ophthalmol Auckl NZ. 2023;17:1385–94.
11. Miller VJ Outcomes of Kahook Dual Blade goniotomy for uveitis associated open-angle glaucoma or ocular hypertension J Glaucoma 2022 31 903 908 10.1097/IJG.0000000000002099 35980845
Miller VJ, et al. Outcomes of Kahook Dual Blade goniotomy for uveitis associated open-angle glaucoma or ocular hypertension. J Glaucoma. 2022;31:903–8.35980845
12. Iwasaki K Long-term outcomes of a Kahook Dual Blade procedure combined with phacoemulsification in Japanese patients with open-angle glaucoma J Clin Med 2022 11 1354 10.3390/jcm11051354 35268445
Iwasaki K, et al. Long-term outcomes of a Kahook Dual Blade procedure combined with phacoemulsification in Japanese patients with open-angle glaucoma. J Clin Med. 2022;11:1354.35268445
13. Albuainain A Al Habash A Three-year clinical outcomes of phacoemulsification combined with excisional goniotomy using the Kahook Dual Blade for cataract and open-angle glaucoma in Saudi Arabia Saudi J Ophthalmol 2022 36 213 217 10.4103/sjopt.sjopt_182_21 36211318
Albuainain A, Al Habash A. Three-year clinical outcomes of phacoemulsification combined with excisional goniotomy using the Kahook Dual Blade for cataract and open-angle glaucoma in Saudi Arabia. Saudi J Ophthalmol. 2022;36:213–7.36211318
14. Wagner IV Long-term efficacy of successful excisional goniotomy with the Kahook Dual Blade Clin Ophthalmol Auckl NZ 2024 18 713 721 10.2147/OPTH.S451002
Wagner IV, et al. Long-term efficacy of successful excisional goniotomy with the Kahook Dual Blade. Clin Ophthalmol Auckl NZ. 2024;18:713–21.
15. Dorairaj S Tam MD Kahook Dual Blade excisional goniotomy and goniosynechialysis combined with phacoemulsification for angle-closure glaucoma: 6-month results J Glaucoma 2019 28 643 646 10.1097/IJG.0000000000001256 30950968
Dorairaj S, Tam MD. Kahook Dual Blade excisional goniotomy and goniosynechialysis combined with phacoemulsification for angle-closure glaucoma: 6-month results. J Glaucoma. 2019;28:643–6.30950968
16. Dorairaj S Tam MD Balasubramani GK Twelve-month outcomes of excisional goniotomy using the Kahook Dual Blade® in eyes with angle-closure glaucoma Clin Ophthalmol Auckl NZ 2019 13 1779 1785 10.2147/OPTH.S221299
Dorairaj S, Tam MD, Balasubramani GK. Twelve-month outcomes of excisional goniotomy using the Kahook Dual Blade® in eyes with angle-closure glaucoma. Clin Ophthalmol Auckl NZ. 2019;13:1779–85.
17. Dorairaj S Tam MD Balasubramani GK Two-year clinical outcomes of combined phacoemulsification, goniosynechialysis, and excisional goniotomy for angle-closure glaucoma Asia-Pac J Ophthalmol Phila Pa 2020 10 183 187 10.1097/APO.0000000000000321
Dorairaj S, Tam MD, Balasubramani GK. Two-year clinical outcomes of combined phacoemulsification, goniosynechialysis, and excisional goniotomy for angle-closure glaucoma. Asia-Pac J Ophthalmol Phila Pa. 2020;10:183–7.
18. Al Habash A Albuainain A Long term outcome of combined phacoemulsification and excisional goniotomy with the Kahook Dual Blade in different subtypes of glaucoma Sci Rep 2021 11 10660 10.1038/s41598-021-90223-5 34021228
Al Habash A, Albuainain A. Long term outcome of combined phacoemulsification and excisional goniotomy with the Kahook Dual Blade in different subtypes of glaucoma. Sci Rep. 2021;11:10660.34021228
19. American Academy of Ophthalmology. ICD-10-CM Quick Reference Guide for Glaucoma. San Francisco: American Academy of Ophthalmology; 2015.
20. Radwan L Outcomes of phacoemulsification with or without Kahook Dual Blade goniotomy for glaucoma patients with cataract J Glaucoma 2024 10.1097/IJG.0000000000002429 38747724
Radwan L, et al. Outcomes of phacoemulsification with or without Kahook Dual Blade goniotomy for glaucoma patients with cataract. J Glaucoma. 2024. 10.1097/IJG.0000000000002429.38747724
21. Irie A Trabeculotomy using the Kahook Dual Blade for exfoliation glaucoma and primary open-angle glaucoma: comparison of outcomes according to incision range J Glaucoma 2024 33 270 276 10.1097/IJG.0000000000002323 38506849
Irie A, et al. Trabeculotomy using the Kahook Dual Blade for exfoliation glaucoma and primary open-angle glaucoma: comparison of outcomes according to incision range. J Glaucoma. 2024;33:270–6.38506849
22. Espinoza G Twelve-month outcomes of Kahook Dual Blade goniotomy combined with cataract surgery in Latino patients Int Ophthalmol 2024 44 44 10.1007/s10792-024-03024-w 38337081
Espinoza G, et al. Twelve-month outcomes of Kahook Dual Blade goniotomy combined with cataract surgery in Latino patients. Int Ophthalmol. 2024;44:44.38337081
23. Birnbaum F Postoperative management of Kahook Dual Blade goniotomy with phacoemulsification cataract extraction J Curr Glaucoma Pract 2023 17 169 174 10.5005/jp-journals-10078-1419 38269267
Birnbaum F, et al. Postoperative management of Kahook Dual Blade goniotomy with phacoemulsification cataract extraction. J Curr Glaucoma Pract. 2023;17:169–74.38269267
24. Mochizuki T Surgical outcomes of ab interno trabeculotomy without phacoemulsification Clin Ophthalmol Auckl NZ 2024 18 9 16 10.2147/OPTH.S446168
Mochizuki T, et al. Surgical outcomes of ab interno trabeculotomy without phacoemulsification. Clin Ophthalmol Auckl NZ. 2024;18:9–16.
25. Richter GM Trabecular procedures combined with cataract surgery for open-angle glaucoma: a report by the American Academy of Ophthalmology Ophthalmology 2024 131 370 382 10.1016/j.ophtha.2023.10.009 38054909
Richter GM, et al. Trabecular procedures combined with cataract surgery for open-angle glaucoma: a report by the American Academy of Ophthalmology. Ophthalmology. 2024;131:370–82.38054909
26. Salimi A Outcomes and risk factors for Kahook Dual Blade excisional goniotomy with concomitant phacoemulsification: a multicentre Canadian study Can J Ophthalmol 2023 S0008–4182 23 00249 251 10.1016/j.jcjo.2023.08.004
Salimi A, et al. Outcomes and risk factors for Kahook Dual Blade excisional goniotomy with concomitant phacoemulsification: a multicentre Canadian study. Can J Ophthalmol. 2023;S0008–4182(23):00249–51. 10.1016/j.jcjo.2023.08.004.
27. Bravetti GE Surgical outcomes of excisional goniotomy using the Kahook Dual Blade in severe and refractory glaucoma: 12-month results Eye 2023 37 1608 1613 10.1038/s41433-022-02196-y 35945340
Bravetti GE, et al. Surgical outcomes of excisional goniotomy using the Kahook Dual Blade in severe and refractory glaucoma: 12-month results. Eye. 2023;37:1608–13.35945340
28. Harvey BJ Khaimi MA A review of canaloplasty Saudi J Ophthalmol 2011 25 329 336 10.1016/j.sjopt.2011.08.003 23960946
Harvey BJ, Khaimi MA. A review of canaloplasty. Saudi J Ophthalmol. 2011;25:329–36.23960946
29. Robin AL Novack GD Covert DW Crockett RS Marcic TS Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use Am J Ophthalmol 2007 144 533 540.e2 10.1016/j.ajo.2007.06.012 17686450
Robin AL, Novack GD, Covert DW, Crockett RS, Marcic TS. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol. 2007;144:533-540.e2.17686450
30. Rodica L Peculiarities of ocular and systemic pathology in the elderly J Ophthalmol Adv Res. 2022 10.4688/JOAR.2022.3206
Rodica L. Peculiarities of ocular and systemic pathology in the elderly. J Ophthalmol Adv Res. 2022. 10.46889/JOAR.2022.3206.
31. Carter TL. Age-related vision changes: a primary care guide. Geriatrics. 1994;49:37–42, 45 (quiz 46–47)
32. Ehrlich R Age-related ocular vascular changes Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol. 2009 247 583 591 10.1007/s00417-008-1018-x
Ehrlich R, et al. Age-related ocular vascular changes. Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol. 2009;247:583–91.
33. Wyatt HJ Dul MW Swanson WH Variability of visual field measurements is correlated with the gradient of visual sensitivity Vis Res 2007 47 925 936 10.1016/j.visres.2006.12.012 17320924
Wyatt HJ, Dul MW, Swanson WH. Variability of visual field measurements is correlated with the gradient of visual sensitivity. Vis Res. 2007;47:925–36.17320924
34. Rabiolo A Quantification of visual field variability in glaucoma: implications for visual field prediction and modeling Transl Vis Sci Technol 2019 8 25 10.1167/tvst.8.5.25 31637105
Rabiolo A, et al. Quantification of visual field variability in glaucoma: implications for visual field prediction and modeling. Transl Vis Sci Technol. 2019;8:25.31637105
35. Giammaria S Rates of visual field change in patients with glaucoma and healthy individuals JAMA Ophthalmol 2022 140 504 511 10.1001/jamaophthalmol.2022.0671 35389449
Giammaria S, et al. Rates of visual field change in patients with glaucoma and healthy individuals. JAMA Ophthalmol. 2022;140:504–11.35389449
36. Garway-Heath DF Evaluation of visual field and imaging outcomes for glaucoma clinical trials (an American Ophthalmological Society Thesis) Trans Am Ophthalmol Soc 2017 115 T4 29085257
Garway-Heath DF, et al. Evaluation of visual field and imaging outcomes for glaucoma clinical trials (an American Ophthalmological Society Thesis). Trans Am Ophthalmol Soc. 2017;115:T4.29085257
37. Smith SD Katz J Quigley HA Analysis of progressive change in automated visual fields in glaucoma Investig Ophthalmol Vis Sci 1996 37 1419 1428 8641844
Smith SD, Katz J, Quigley HA. Analysis of progressive change in automated visual fields in glaucoma. Investig Ophthalmol Vis Sci. 1996;37:1419–28.8641844
38. Chauhan BC Nicolela MT Artes PH Incidence and rates of visual field progression after longitudinally measured optic disc change in glaucoma Ophthalmology 2009 116 2110 2118 10.1016/j.ophtha.2009.04.031 19500850
Chauhan BC, Nicolela MT, Artes PH. Incidence and rates of visual field progression after longitudinally measured optic disc change in glaucoma. Ophthalmology. 2009;116:2110–8.19500850
39. Heijl A Buchholz P Norrgren G Bengtsson B Rates of visual field progression in clinical glaucoma care Acta Ophthalmol (Copenh) 2013 91 406 412 10.1111/j.1755-3768.2012.02492.x
Heijl A, Buchholz P, Norrgren G, Bengtsson B. Rates of visual field progression in clinical glaucoma care. Acta Ophthalmol (Copenh). 2013;91:406–12.
40. Aptel F Progression of visual field in patients with primary open-angle glaucoma—ProgF study 1 Acta Ophthalmol (Copenh) 2015 93 e615 620 10.1111/aos.12788
Aptel F, et al. Progression of visual field in patients with primary open-angle glaucoma—ProgF study 1. Acta Ophthalmol (Copenh). 2015;93:e615-620.
41. Machiele R, Motlagh M, Zeppieri M, Patel BC. Intraocular pressure. In: Pi J (ed.) StatPearls. Treasure Island: StatPearls Publishing; 2024.
